H. Lundbeck A/S (HLBBF)

Market Cap	5.38B
Revenue (ttm)	3.21B
Net Income (ttm)	401.88M
Shares Out	n/a
EPS (ttm)	0.41
PE Ratio	13.38
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	105
Open	5.65
Previous Close	6.10
Day's Range	5.65 - 5.65
52-Week Range	4.63 - 7.13
Beta	0.21
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 5, 2025

About H. Lundbeck

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat M...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1951
• Employees: 5,681
• Stock Exchange: OTCMKTS
• Ticker Symbol: HLBBF

Financial Performance

In 2023, H. Lundbeck's revenue was 19.91 billion, an increase of 9.13% compared to the previous year's 18.25 billion. Earnings were 2.29 billion, an increase of 19.52%.

Financial numbers in DKK